Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    120

Stocks News & Analysis

stocks

AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
stocks

The most popular ASX trades in FY26

A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.
stocks

Chart of the Week: The CBA chart you can’t ignore

Where value remains in Australian banks.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,018.1041.40-0.46%
CAC 408,299.09138.80-1.64%
DAX 4024,763.12392.29-1.56%
Dow JONES (US)51,711.65506.93-0.97%
FTSE 10010,639.1777.80-0.73%
HKSE25,210.81318.151.28%
NASDAQ25,137.69553.21-2.15%
Nikkei 22566,422.60307.000.46%
NZX 50 Index13,795.3132.130.23%
S&P 5007,408.3090.66-1.21%
S&P/ASX 2008,839.0038.60-0.43%
SSE Composite Index3,876.789.740.25%

Market Movers